Prof. Hongsheng Liu | Pharmaco-Oncology | Best Researcher Award

Prof. Hongsheng Liu | Pharmaco-Oncology | Best Researcher Award

Liaoning University | China

Author Profile

Scopus

🌟 Professor Hongsheng Liu: A Pioneer in Microbiology and Bioinformatics

Professor, School of Pharmaceutical Sciences, Liaoning University, China

🔬 Academic and Professional Background

Professor Hongsheng Liu obtained a Master’s degree in Microbiology from China Agricultural University in 1991 and later pursued a Ph.D. in Microbiology and Bioinformatics at Gifu University School of Medicine, Japan, in 2004. Over the years, he has expanded his expertise by serving as a visiting scholar at prestigious institutions such as Wuhan University, the University of Hong Kong, Harvard Medical School, and Hebrew University of Jerusalem. His career reflects a deep commitment to advancing the fields of microbiology, bioinformatics, and pharmaceutical sciences.

💡 Research and Innovations

Professor Liu has completed an impressive 74 research projects and authored over 100 journal articles (SCI, Scopus, etc.), accumulating a citation index of 2721. His work spans diverse areas, including the discovery of the novel microorganism Paenibacillus liaoningensis sp. nov. and the investigation of influenza virus interactions. His contributions to computational biology include the development of several predictive algorithms and online platforms like CarcinoPred-EL and LiverToxPred-EL. Additionally, Professor Liu holds 37 patents, has published 4 books, and has led 7 industry consultancy projects.

📚 Published Works and Collaborations

Professor Liu’s collaborative research includes partnerships with renowned institutions such as the University of Toledo, Harvard Medical School, and Eberhard Karl University of Tübingen. He has also served as a guest editor for Frontiers in Microbiology (2017-2018). His dedication to both basic and applied research continues to push the boundaries of pharmaceutical sciences.

👥 Professional Memberships

He is an active member of the Chinese Society for Microbiology (CSM) and the Chinese Chemical Society (CCS).

🌍 Areas of Research

Professor Liu specializes in computer-aided drug design and the simulation of biomacromolecule interactions, with a focus on studying lncRNAs and disease relationships, and designing stable recombinant proteins using engineered bacteria.

🔔 Conclusion

Professor Hongsheng Liu stands as a distinguished leader in microbiology and bioinformatics, contributing significantly to drug design, biomolecular simulation, and microbial discovery. His broad academic collaborations, cutting-edge innovations, and vast research output underscore his influence in the scientific community. Through his extensive work on predictive algorithms, microbial databases, and recombinant protein design, he has made impactful advancements in pharmaceutical sciences. With over 100 journal publications, 37 patents, and numerous prestigious collaborations, Professor Liu’s dedication to advancing scientific knowledge and improving human health is truly commendable.

📊🔬NOTABLE PUBLICATION:

    • Article Title: Ensemble multiclassification model for aquatic toxicity of organic compounds
      Authors: Li, X., Liu, G., Wang, Z., Liu, H., Ai, H.
      Journal: Aquatic Toxicology
      Year: 2023

     

    • Article Title: Construction of an oxidative stress-related lncRNAs signature to predict prognosis and the immune response in gastric cancer
      Authors: Zhang, H., Feng, H., Yu, T., Ma, L., Liu, H.
      Journal: Scientific Reports
      Year: 2023

     

    • Article Title: CBIL-VHPLI: a model for predicting viral-host protein-lncRNA interactions based on machine learning and transfer learning
      Authors: Zhang, M., Zhang, L., Liu, T., Zhao, J., Liu, H.
      Journal: Scientific Reports
      Year: 2024

     

    • Article Title: Construction of highly active and stable recombinant nattokinase by engineered bacteria and computational design
      Authors: Wang, L., Meng, J., Yu, X., Zhang, L., Liu, H.
      Journal: Archives of Biochemistry and Biophysics
      Year: 2024

     

    • Article Title: Effects of dietary supplementation of gallic tannic acid on growth, intestinal digestive enzymes activity, innate immunity, morphology, and microbial composition of Cyprinus carpio
      Authors: Feng, H., Zhao, S., Ma, X., Liu, Z., Liu, H.
      Journal: Aquaculture International
      Year: 2024

Mrs. Anke van Engen | Clinical Health Technology | Best Researcher Award

Mrs. Anke van Engen | Clinical Health Technology | Best Researcher Award

IQVIA | Netherlands 

Author Profile

Scopus

🌍Mrs. Anke van Engen 💼

  • Managing Principal, IQVIA Payer Evidence Solutions
    Amsterdam, the Netherlands

🔬Profile:

  • Anke van Engen is a seasoned expert with over 20 years of experience in health economics, outcomes research, and market access strategy. Her work focuses on helping life sciences companies achieve greater commercial success through integrated payer evidence strategies. Anke is well-regarded for building lasting partnerships, consistently delivering results, and serving as a trusted advisor to clients. She excels at leading international teams across EMEA, using her coaching and training abilities to inspire success.

👨‍⚕️Key Specialties:

  • 📚General management
  • 🌍Strategic planning & business development
  • 🩺Health economics & outcomes research (HEOR)
  • 🏥Market access strategy (MA) & execution
  • 💉Health technology assessment (HTA)
  • 📍Client relationship management & coaching

💼Professional Experience:

  • 🌟2023 – Present: Managing Principal, IQVIA Value & Payer Evidence
    • Co-leads EMEA Real World Evidence Leadership Team
    • Oversees integrated evidence & EU HTA offerings
  • 💡2020 – 2023: Senior Principal, IQVIA Real World Solutions
    • Led the development of EMEA payer evidence solutions
    • Drove go-to-market strategy and key client partnerships
  • 🌐2017 – 2020: Senior Principal, IQVIA Consulting Services
    • Managed partnerships with large pharmaceutical clients
    • Led the HTA Accelerator solution for launch readiness
  • 🚀2014 – 2017: Principal, Quintiles Advisory Services
    • Led development of the flagship HTA Accelerator platform
    • Senior oversight on HEOR/MA strategy and projects

🎓Education:

  • 🧪MSc in Chemistry (Bio-organic Chemistry), University of Leiden, The Netherlands
  • 📊Business leadership programs at IMD, Lausanne, Switzerland

🌐Professional Affiliations:

  • 🧬Active member of ISPOR and HTAi
  • 💡IQVIA representative at GetReal Institute

🏅Awards & Honors:

  • 🌟2023: Issue panel ranked #1 at ISPOR Europe
  • 🦈2014: Won Sharktank contest for HTA Accelerator innovation
  • 🏆Multiple ISPOR awards for best podium and poster presentations

 

🔍 Conclusion
  • 💼In conclusion, Anke van Engen is a highly respected leader in the field of health economics, outcomes research, and market access strategy, with a proven track record of guiding life sciences companies toward commercial success. Her expertise in building long-term client partnerships, managing international teams, and delivering innovative payer evidence solutions has solidified her reputation as a trusted advisor. With over two decades of experience and numerous accolades, Anke continues to shape the future of healthcare consultancy by integrating strategic insights and real-world evidence. 🌍

 

📊🔬NOTABLE PUBLICATION:

 

    • The Impact of Additive PICOs in a European Union Joint Clinical Health Technology Assessment
      • Authors: van Engen A, Krüger R, Parnaby A, Rotaru M, Ryan J, Samaha D, Tzelis D
      • Journal: Value Health
      • Year: 2024

     

    • Use of External Comparators for Health Technology Assessment (HTA) Submissions Based on Single-Arm Trials
      • Authors: Patel D, Grimson F, Mihaylova E, Wagner P, Warren J, van Engen A, Kim J
      • Journal: Value Health
      • Year: 2021

     

    • Call in the PROs: Giving Credence to the Patient’s Perspective in Healthcare Decision Making
      • Authors: van Engen A, New M, Beatrice Böhler Y, Holmstrom S, Boerlum Kristensen F
      • Journal: ISPOR Value & Outcomes Spotlight
      • Year: 2020